LP
JAZZ icon

LMR Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

LMR Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-64,700
Closed -$11M – 1670
2025
Q4 		$11M Buy
64,700
+57,900
+851% +$8.88M 0.02% 351
2025
Q3 		$896K Buy
+6,800
New +$816K ﹤0.01% 967
2024
Q4 		– Sell
-5,981
Closed -$666K – 1401
2024
Q3 		$666K Hold
5,981
– – 0.01% 784
2024
Q2 		$638K Buy
+5,981
New +$658K 0.01% 736
2016
Q3 		– Sell
-25,360
Closed -$3.58M – 413
2016
Q2 		$3.58M Buy
+25,360
New +$3.74M 0.56% 34
2014
Q4 		– Sell
-118,337
Closed -$19M – 418
2014
Q3 		$19M Buy
+118,337
New +$18.2M 1.51% 17
2014
Q2 		– Sell
-125,237
Closed -$17.4M – 506
2014
Q1 		$17.4M Buy
+125,237
New +$18.9M 2.43% 13

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

LMR Partners's JAZZ Position: Q1 2026 in Review

LMR Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 64,700 shares — an estimated $11M sold.

LMR Partners first reported a position in JAZZ in Q1 2014 and held it in 7 quarters. The position peaked at $19M in Q3 2014. 573 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • LMR Partners reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • LMR Partners sold 64,700 Jazz Pharmaceuticals shares in Q1 2026, an estimated $11M.
  • LMR Partners first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 7 quarters.
  • LMR Partners's Jazz Pharmaceuticals position peaked at $19M in Q3 2014.
  • 573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.